Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat plus azacitidine versus placebo plus azacitidine in newly diagnosed AML unfit for intensive induction
2016-004724-34Phase 3Terminated
- Sponsor
- Helsinn
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Pracinostat + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Started Apr 2017; status: terminated.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-004724-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004724-34.